A randomized, double-blind, placebo-controlled trial of 5-fluorouracil for the treatment of cervicovaginal human papillomavirus
Melisa Holmes, Simon Weaver, Stephen T. Vermillion
Infectious Diseases in Obstetrics and Gynecology, Vol. 7, Issue 4, pp. 186–189 (1999)
10.1002/(sici)1098-0997(1999)7:4<186::aid-idog4>3.0.co;2-z
PMID: 10449266
Abstract
OBJECTIVE: To compare intravaginal 5-fluorouracil (5-FU) and placebo for the treatment of cervical and/or vaginal human papillomavirus (HPV). METHODS: A randomized, placebo-controlled trial was performed. Women with HPV detected visually or by Papanicolaou (Pap) test and confirmed by colposcopic biopsy were randomized to receive either intravaginal 5-FU cream or an intravaginal placebo cream. Women with cervical or vaginal intraepithelial neoplasia were excluded. The primary outcome measure was cytologic regression of HPV as determined by Pap test screening 4 to 6 months after treatment. The secondary outcome was cytologic evidence of disease progression at both the 4-6-month and 12-month follow-up evaluations. Data were analyzed using the Chi square test with significance established at P < 0.05. RESULTS: A total of forty patients were randomized, and thirty patients had a follow-up Pap test 4 to 6 months after treatment. Of those patients treated with 5-FU, 28% demonstrated regression of HPV on cytologic evaluation, compared with 69% of those treated with placebo (P < 0.05). Twelve-month follow-up cytology was available from 18 of the study participants. There were no significant differences in the frequency of cytologic progression or regression between groups at 12 months. CONCLUSION: Four to six months post treatment, the use of intravaginal 5-FU for the treatment of cervical or vaginal HPV is associated with a lower rate of regression than the use of placebo.
Topics
Field: Medicine · Subfield: Epidemiology
Keywords
Medicine,Placebo,Papanicolaou stain,Cervical intraepithelial neoplasia,Gynecology,Cytology,Randomized controlled trial,Cervical cancer,Internal medicine,Cancer
MeSH Terms
UN Sustainable Development Goals
- Good health and well-being (0.86)
All Available Versions
- PDF Landing page — Infectious Diseases in Obstetrics and Gynecology publishedVersion
- Landing page — PubMed publishedVersion
Citations by Year
| 2026 | 2023 | 2022 | 2021 | 2020 | 2018 | 2016 | 2015 | 2013 |
|---|---|---|---|---|---|---|---|---|
| 2 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 |
Continue on JournalsHub
Put what you just read into practice with these free tools.